NASDAQ: ICUI · Medical Instruments & Supplies

ICU Medical (ICUI) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values ICU Medical (ICUI) at $202.62 a share. The stock last closed at $181.87, which puts the model's fair value 11.4% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. ICU Medical, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$202.62midpoint of 2,000 simulations
Last close$181.87NASDAQ: ICUI
Gap to fair value+11.4%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $192.51 to $202.62 (+5.3%). The companies the model compares it with now trade on higher multiples: part of the move.

What the model makes of itThe price of $181.87 is 11.4% below it: Fairly valued, on a high evidence grade.

What's nextNext report on 18 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ICUI?

The calibrated range for ICUI over 63 trading days is $161.06 to $206.64. It sits around the last close, and its width comes from the volatility that ICUI's own options imply (37% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $164.60 to $245.64. In 68% of the simulations the fair value came out above the price the model ran on.

$126.97$315.35
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $202.62. Dashed line: the last close, $181.87.

Faircurve Insights · 14 Nov 2026

ICU Medical, Inc. is a medical technology firm that develops, manufactures and sells devices for infusion therapy and critical care. It operates globally through its subsidiaries.

Faircurve's model put the fair value at $202.62 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $192.51, so the fair value moved +5.3%. In the model's words, "The companies the model compares it with now trade on higher multiples: part of the move." The range over 63 trading days is $161.06 to $206.64. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations. The evidence grade is High. It looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

On quality, the model scores ICU Medical 51 out of 100 against comparable companies. Earnings quality is strongest at 83, with free cash flow at 3.46x net income against a peer median of 1.20x. Growth quality is weakest at 18, with trailing revenue growth of -6.4% against a peer median of 5.7%. The comparison set is Merit Medical Systems, Teleflex, AptarGroup, Avantor, Repligen, DENTSPLY SIRONA and LeMaitre Vascular.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ICUI report earnings, and how has the stock reacted?

ICU Medical's next earnings report is scheduled for 18 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 8.6% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ICUI's 30 day implied volatility works out to about 10.6% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ICUI's last 8 reports, ignoring direction, was 5.4%.

0%5%10%15%14.2%1.9%12 Nov '24no quote5.1%27 Feb '25no quote11.1%7 Aug '25no quote10.0%6 Nov '25no quote3.6%19 Feb '26no quote5.7%7 May '26no quote10.9%6 Aug '269.3%0.3%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in ICUI

5%10%15%20%5 Nov '26 report6 Aug '26 report7 May '26 report19 Feb '26 report11% at 16 Nov '2611 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 11% on 11 Nov 2025, reached 17% on 19 Feb 2026 and reads 11% on 16 Nov 2026. The marks are report dates.

How does ICUI score on business quality?

ICU Medical's overall quality score is 51 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.484.8%ROIC6.8%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).833.46xFCF / net income1.20x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.18-6.4%Revenue growth, trailing5.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.790.2%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.322.98xNet debt / EBITDA1.28x
StabilityDownside volatility of the EBITDA margin over the last five years.571.8 ptsEBITDA margin downside volatility, 5y2.0 pts

How does ICUI compare with similar companies?

The companies in medical instruments & supplies closest to ICU Medical in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
NVST Envista Holdings Corp$24.03$25.54+6.3%Low evidence grade
MMSI Merit Medical Systems, Inc.$86.35$82.63-4.3%Fairly valued
TFX Teleflex Incorporated$157.10$169.00+7.6%Fairly valued
ATR AptarGroup, Inc.$143.17$137.10-4.2%Fairly valued
AVTR Avantor, Inc.$15.32$20.70+35.1%Undervalued
RGEN Repligen Corporation$162.78$152.66-6.2%Fairly valued
XRAY DENTSPLY SIRONA Inc.$8.95$13.35+49.2%Undervalued
LMAT LeMaitre Vascular, Inc.$77.01$93.66+21.6%Undervalued

What the comparable companies' multiples alone would give for ICUI, the peer-implied price, is $271.31 a share on this run. The fair value weighs that against the company's own multiple.

All medical instruments & supplies stocks ranked by gap to fair value

ICU Medical at a glance

ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care.

Market value
$4.5B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Revenue expected, next twelve months
$2.3B
Consensus revenue growth, next fiscal year
-1.8%
Analysts with estimates
6
Beta to the US market
0.90
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ICUI was among them.

How the fair value is worked out: the model prices ICU Medical on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ICUI was $192.51. As of 14 Nov 2026 it is $202.62, a change of +5.3%. The companies the model compares it with now trade on higher multiples: part of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about ICU Medical's valuation

Is ICU Medical stock undervalued or overvalued?

On Faircurve's model, ICUI reads as Fairly valued as of 14 Nov 2026. The model's fair value is $202.62 a share against a last close of $181.87, a gap of +11.4%.

What is ICUI's fair value?

$202.62 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $164.60 to $245.64.

What price range does the model give ICUI?

$161.06 to $206.64 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does ICU Medical report earnings next?

The next report is scheduled for 18 Feb 2027. Companies can move their dates.

How much has ICUI moved on past earnings reports?

Across its last 8 reports the median two session move was 5.4%, ignoring direction. The largest was -11.1% around the report of 7 Aug 2025.

How confident is the model in this valuation?

The model's evidence grade for ICUI is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ICUI

The model holds no idea open on ICUI today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ICUI with their outcomes. A free account is enough.

Keep reading